Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Neuroblastoma × racotumomab × Clear all

Phase

Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Small Cell Lung Carcinoma 1 Neuroblastoma 1

Interventions

Cyclophosphamide 29 Etoposide 21 Isotretinoin 18 Topotecan 16 Temozolomide 16 Doxorubicin 16 Irinotecan 15 Carboplatin 15 Vincristine 14 sargramostim 13 Melphalan 12 Granulocyte-Macrophage Colony-Stimulating Factor 12 3-Iodobenzylguanidine 12 Radiotherapy 11 Cisplatin 11 dinutuximab 10 Magnetic Resonance Spectroscopy 9 Filgrastim 9 naxitamab 8 Peripheral Blood Stem Cell Transplantation 8 Thiotepa 7 humanized 3F8 anti-GD2 monoclonal antibody 6 X-Rays 6 Specimen Handling 6 Phantoms, Imaging 6 Granulocyte Colony-Stimulating Factor 6 Busulfan 6 Antilymphocyte Serum 6 fludarabine phosphate 5 aldesleukin 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02998983 2023-09-11

Racotumomab in Patients With High-risk Neuroblastoma

Laboratorio Elea Phoenix S.A.

Phase 2 Completed

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡